Tag Archives: Alzheimer’s

Is this worth taking?

No Gravatar

Lecanemab.

Is it really working?

So, the data seems to indicate that administering this drug will retard cognitive and functional decline by 27%, when compared to a placebo.  That’s good news for Eisai and Biogen- as well as perhaps for Eli Lilly which is concurrently testing its own anti-amyloid drug for Alzheimer’s.

Continue reading Is this worth taking?

Share this:
Share this page via Email Share this page via Stumble Upon Share this page via Digg this Share this page via Facebook Share this page via Twitter
Share

In Vitro Alzheimer’s Test

No Gravatar

It’s always great when there’s competition.

(Yes, I know the problem in America is that we no longer have capitalism- instead, our politicians have enshrined crony capitalism, where we grant favors to certain companies [and those are the ones that donate all those funds for their political campaigns].   But, it’s possible for us to re-enshrine capitalism as the partner for our democracy (there’s another institution that is endangered here in America, thanks to TheDonald and his buddies at qAnon)- so we really can re-stablish the American Dream, where anyone with a good idea, a little bit of luck and a lot of hard work can become successful.  But, enough about politics.  Let’s get back to science.)

Continue reading In Vitro Alzheimer’s Test

Share this:
Share this page via Email Share this page via Stumble Upon Share this page via Digg this Share this page via Facebook Share this page via Twitter
Share

Alzheimers- but not Aduhelm

No Gravatar

So,  as we’ve discussed over the past few days (check yesterday’s blog, if you want), the FDA approved Aduhelm, the monoclonal antibody that attaches to amyloid.  The problem is that there is no clinical data demonstrating this will help alleviate the memory loss in Alzheimer’s patients- despite the FDA approval.

Continue reading Alzheimers- but not Aduhelm

Share this:
Share this page via Email Share this page via Stumble Upon Share this page via Digg this Share this page via Facebook Share this page via Twitter
Share

The FDA responds to blistering complaints

No Gravatar
I devoted two posts to the Aduhelm/Alzheimer’s controversy. (The most recent one was yesterday.) Today, I will post (the FDA verbiage in black ink, with my editorial comments in red print) the FDA’s reasoning (sic) as to why it overrode the recommendations of its qualified experts.

Continue reading The FDA responds to blistering complaints

Share this:
Share this page via Email Share this page via Stumble Upon Share this page via Digg this Share this page via Facebook Share this page via Twitter
Share